Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities
Sets out how to derive a health-based exposure limit — the permitted daily exposure — from toxicological and clinical data, for use in assessing cross-contamination risk where different medicinal products share a facility. Adopted 20 November 2014, effective 1 June 2015.
What this does not cover
stated in the document's own scope- It sets a method for deriving exposure limits; it does not itself decide whether a facility must be dedicated. That decision is made under EU GMP Chapter 3, using the limit as an input.
- Active pharmaceutical ingredients are not addressed by GMP Chapters 3 and 5, although the guideline says its principles may be applied to them where required.
- Therapeutic macromolecules and peptides that are degraded and inactivated by cleaning conditions may not need a PDE for the intact product; other cross-contamination routes are assessed case by case.
- It is not an occupational-exposure standard. Limits protecting the people who handle a substance are set under occupational health and safety law, not by this guideline.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The EMA guideline on setting health based exposure limits sets out how a manufacturer should derive a scientifically based threshold for each active substance made in a shared facility, so that the risk of one product contaminating another can be identified on a toxicological basis. Its central tool is the Permitted Daily Exposure (PDE): a substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below it every day for a lifetime. The same value can then be used to justify the carry-over limits applied in cleaning validation. It was adopted jointly by the human-medicines committee (CHMP) and the veterinary committee (CVMP).
Scope & applicability
Shared manufacturing facilities, and the determination of whether dedicated facilities are required. It is the document that moved cleaning-validation limits away from arbitrary conventions such as one-thousandth of a dose or ten parts per million and onto a toxicological basis — which is also the basis on which an occupational exposure limit is derived, from the same underlying assessment.
Legal basis & how it acquires force
This is a scientific guideline of the European Medicines Agency, reference EMA/CHMP/CVMP/SWP/169430/2012. The CVMP adopted it on 11 September 2014 and the CHMP on 20 November 2014, with a date for coming into effect of 1 June 2015. Its own legal-basis section says it is to be read in conjunction with Chapters 3 and 5 of the EU GMP Guide (EudraLex Volume 4), which were revised to call for a "toxicological evaluation" when establishing threshold values. The binding duty sits in GMP; the guideline is the method EMA recommends for meeting it, and it allows a different approach if adequately justified.
Document structure
| Part | Covers |
|---|---|
| Executive summary, introduction and scope | Why shared facilities need health-based limits, and the populations protected — human patients, target animals and consumers of food from treated animals |
| 3. Legal basis | Reading the guideline with EU GMP Chapters 3 and 5, the residual-solvent guidance (ICH Q3C and VICH GL18) and the genotoxic-impurity guideline |
| 4. Determination of health based exposure limits | Calculating the PDE from a NOAEL with adjustment factors F1 to F5, the use of clinical data, and route-to-route extrapolation |
| 5. Specific considerations | Genotoxic substances, highly sensitising substances, therapeutic macromolecules and peptides, missing reproductive-toxicity data, and investigational medicinal products |
| 6–7. Reporting and implementation | How the PDE determination strategy is documented and the phased dates by which it took effect |
| Annex | A template summary page for the PDE determination strategy, signed by the expert who prepared it |
Key requirements
- Derivation of a permitted daily exposure from a point of departure with justified adjustment factors
- Use of the PDE in cross-contamination risk assessment and in setting cleaning acceptance limits
- Assessment by a person with appropriate toxicological or pharmacological expertise, with the derivation documented
- Identification of compounds requiring dedicated or segregated facilities rather than shared ones
Implementation tips
- One toxicological assessment serves two obligations: the PDE that drives cleaning limits and the occupational exposure limit that drives containment. Commissioning them separately duplicates cost and can produce two numbers that disagree
- The derivation is the deliverable, not the number — a PDE without its point of departure and adjustment-factor rationale cannot be defended or updated when new data arrive
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The guideline borrows its PDE method directly from Appendix 3 of ICH Q3C (residual solvents) and Appendix 3 of VICH GL18, so the same equation is used for a solvent residue and for a residual active substance. For genotoxic substances without a threshold it applies the Threshold of Toxicological Concern of 1.5 µg per person per day taken from the EMA guideline on genotoxic impurities. Because CHMP and CVMP adopted it together, one approach covers human and veterinary manufacture, with PDEs derived assuming human exposure and expressed per kilogram of body weight.
EMA/CHMP/CVMP/SWP/169430/2012: frequently asked questions
Quick answers to common questions about EMA/CHMP/CVMP/SWP/169430/2012.
How is a PDE calculated under the EMA guideline?
The PDE equals the no-observed-adverse-effect level (NOAEL) multiplied by a weight adjustment, divided by the product of five adjustment factors: F1 for extrapolation between species (2 to 12), F2 for variability between individuals (10), F3 for short repeat-dose studies (10), F4 for severe toxicity (1 to 10) and F5 where no no-effect level was established (up to 10).
When did the guideline take effect?
The cover page gives 1 June 2015 as the date for coming into effect. Section 7 phased it in: six months after publication for products newly introduced into shared facilities, one year for existing human-medicine manufacturers, and two years for manufacturers producing only veterinary products.
Who should derive the PDE?
The guideline expects an expert review. The determination must document the literature search, the choice of critical effect and adjustment factors, and begin with a summary page — the Annex template — that records the expert name, signature and a summary of the expert’s CV.
What if the substance is an early-phase investigational product with little data?
Section 5.5 allows default categories based on expected potency, toxicity and genotoxicity, similar to tiered Threshold of Toxicological Concern approaches, where a compound-specific PDE cannot yet be estimated. As data accumulate, a compound-specific limit should replace the default.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.